



Registered & Corporate Office:
AMANTA HEALTHCARE LIMITED
8th Floor, Shaligram Corporates, CJ Marg,
Ambli, Ahmedabad-380058, Gujarat, INDIA.
Tel.: 079 – 67777600
Email: info@amanta.co.in
Website: www.amanta.co.in

CIN: L24139GJ1994PLC023944

February 11, 2026

To, Sr. General Manager Listing Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: 544502	To, Sr. General Manager National Stock Exchange of India Limited Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051. Trading Symbol: AMANTA
--	---

Dear Sir/ Madam,

Sub: Investors Presentation on Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025

Please find enclosed the Investors Presentation on Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

You are requested to take the same on your records.

Thanking you.

Yours sincerely,

For AMANTA HEALTHCARE LIMITED

Dinodia

Nikhita

NIKHITA DINODIA

Company Secretary &

Compliance Officer

Membership No. 53362

Digitally signed by Dinodia Nikhita
DN: c=IN, o=Personal, title=8566,
pseudoym=2110201e14824716bc7c8b71ae22dc,
2.5.4.20=de519ca22899c22053af79ed52285d91e5f,
06355edec1ca48484971a1a443a, postalCode=380028,
st=Gujarat,
serialNumber=81b8b655eb87f922a9a651aad1adc
ba1f0695044d4f48b498a62779ad541684, cn=Dinodia
Nikhita
Date: 2026.02.11 14:07:38 +05'30'

Encl.: As above



Amanta Healthcare Limited

Q3 & 9M FY26 Investor Presentation

Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Amanta Healthcare Ltd.** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.





30+ Years of Sterile Liquids Legacy, A Niche Pharmaceutical Company

Operational Metrics

47	Product Portfolio
7 lines	1 Manufacturing Facility, WHO-GMP Certified
320	Distributors & Stockists
120	International Jurisdictions
506	Team Size
30	Years In Business
21	Countries Generic Products Exported

Financial Metrics

Revenue CAGR (FY21-25): 11.8%
EBITDA CAGR (FY21-25) : 11.6%
ROE (FY25): 12.4%
ROCE (FY25) : 13.7%
Debt to Equity (FY23 to FY25): 3.50x to 2.08x
Net Working Capital Days: 123 days

A fully integrated Sterile Liquid manufacturer and marketer of Large Volume Parenterals (LVPs) and Small Volume Parenterals (SVPs)

Established **SteriPort** brand, which became a generic name.

A preferred choice amongst hospitals and critical medications.

Serving six therapeutic segments, including IV fluids, diluents, ophthalmic, respiratory care and irrigation solutions, using advanced ABFS and ISBM technologies



Built to scale – Amanta’s differentiated business model




RM Sourcing

Key materials Sourced

27.5% LDPE	18.5% TWO PORT CLOSURE SYSTEM	12.5% POLYPROPYLENE
---------------	--	------------------------

Share of total materials imported by Amanta




Top 10 suppliers account for 76% of raw materials consumed



Manufacturing Capabilities

Manufacturing facility in Gujarat spanning 66,852 sq. mts

LVP 4 lines	SVP 3 lines
Total Capacity : 12.28 crore	Total Capacity : 20.91 crore
2 Lines : Conventional Single port bottles	2 Lines: ABFS
2 Lines : Steriport with ISBM technology	1 Line : Conventional 3-piece container



3 Channel Distribution

Robust sales and distribution team with strong presence across the globe

Branded products domestically through 320+ distributors


Exports to emerging and semi-regulated markets

Partners with pharma companies for loan-license manufacturing

Planned expansion into regulated markets including the UK, Zimbabwe, Sudan, Cambodia, the Philippines, and Ethiopia



Company milestones





Types of IV Fluids :

Dextrose, Normal Saline, Combination Of Dextrose Normal Saline, Ringer Lactate, Electrolytes.

Packaging Of Product :


Single Port Container, Two Port Container

Fill Volume Options :

100ml, 250ml, 500ml, 1000ml.

Innovative Technology :

Amanta manufactures SteriPort bottles for IV fluids using ISBM Technology, with polypropylene as the raw material



■ Fluid Therapy

Notable Formulations :

Ciprofloxacin, Metronidazole, Ofloxacin, Paracetamol, Fluconazole.

Packaging Options :


- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)

Fill Volume Range :

2ml to 100ml

Technology :

Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology



■ Formulations

Diluent Product Overview :


- Plain Water for Injection (WFI)
- Normal Saline

Diluents Pack Sizes :

Offered in 5 ml & 10 ml


Injectables Portfolio Key Products :

Lidocaine, Potassium Chloride, Magnesium Sulphate, Calcium Chloride, Calcium Gluconate



■ Diluents & Injectables

Revenue share across all categories



Applications :


Treatment for Infections, Glaucoma, Inflammation.

Dosage Forms :

5ml & 10 ml

Packaging Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack



■ Ophthalmic

Applications :

Administered through nebulisers for the treatment of lungs affected by Asthma or Bronchiectasis


Dosage Form :

Available in 2.5 ml

Key Products :

Respiratory Suspension

- Budesonide,
- Salbutamol
- Salbutamol & Ipratropium Bromide
 - Levosalbutamol
- Levosalbutamol & Ipratropium



■ Respiratory Solutions

Product Types :


OTC Eye Lubricants
Wound Cleaning Solutions

Dosage Forms :

Available in 5 ml, 10 ml & 20 ml

Product :

- Sodium Chloride Eye Wash
 - Wound Cleaning



■ Irrigation Solutions □ Total



Action Plan for the next two years

Wallet Share expansion

Complex dosages and niche molecules across anti-infectives, respiratory care, and Ophthalmics.

Capacity Expansion

Scaling high-margin **SteriPort** and SVP capacities by 5.39 crore and 10.78 crore units, with commissioning in Q1FY27 and Q4FY27, respectively.

Green Energy Initiative and Cost Optimization Techniques

Setting up a solar captive power plant of 10.8 MW which will lead to an expected saving of 9 cr.

Targeting a Revenue CAGR of 20%+ over next two years; EBITDA Margin of 25%+



Well - established Pharma Manufacturer With Diverse Products & Markets

Six therapeutic segments and container systems, 47 products registered in 120 countries.



Wide Domestic And Global Marketing Network

Pan-India network of 320 distributors, 96 sales staff and integrated IT systems.



Large Manufacturing Capabilities

Manufacturing facility in Gujarat spans 66,852 sq. meters, featuring Aseptic BFS and ISBM technologies, with ISO and WHO-GMP certifications



Expert Leadership With Skilled Workforce

Qualified management team with over 30 years of experience, supported by a workforce of over 506 employees (Approx. 1300 with contract workers).





Aseptic Blow Fill Seal (ABFS)

- **Technology:** FFS (Form-Fill-Seal) is used for IV fluid packaging.
- **Process:** Plastic bottles are formed, filled, and sealed in one automated operation without human contact.
- **Features:** Includes nitrogen purging for sensitive formulations like paracetamol.
- **Capacity:** Produces 8 bottles in around 15 seconds.

Injection Stretch-Blow Moulding (ISBM) Technology:

- **Technology:** ISBM (Injection Stretch Blow Moulding) involves multiple stages of operation, unlike FFS.
- **Filling:** Bottles are air washed, WFI washed, dried, filled, and sealed.
- **Process:** Preforms are created, stretched, and blown into bottles from materials like PP (starting at 100 ml).


The Sterilizer:

- **Sterilization Process:** Fully automatic, microprocessor-controlled water shower sterilizer for terminal sterilization.
- **Operation:** Hot water sterilization process duly validated for aseptic & terminally sterilized products



Currently operating at Installed capacity of 6.62 Cr Bottles with 91% Utilization

- Launched the flagship brand in India in 2014
- SteriPort® is preferred by Oncologists, Pediatrician, Intensivist & Anaesthetist
- First-mover advantage enabling better pricing discipline and strong market positioning
- Core revenue driver, contributing 44% of total revenues



Production over the years

■ 2014 ■ Current

What makes it Different?

Material

Random Co-Polymer of Polypropylene

Only material compatible with ISBM technology

Superior tensile strength, barrier properties

superior resistance to high temperature sterilization (121°C)

Process

Absolute Sterility – Terminal Sterilized at 121°C

Single step process – requires no re-heating or re-transferring

100% transparent containers

High-speed, automated production.


Design

Two Port Closure System ensures :

- Leak Free IV Administration
- Dedicated Port for extra medication
- Maintains consistent flow rate



SteriPort (LVP) Expansion in Capacity (In Cr.)



Dedicated capacity within LVP, with 2 of 4 lines supporting **SteriPort®**

Currently operating at 91% utilization, reflecting sustained demand visibility.

5 Cr bottles produced with negligible rejections, underscoring strong manufacturing quality.

LVP Lines	Installed Capacity (Cr Bottles).
Line 1	2.53
Line 2	3.12
SteriPort	
Line 1	5.15
Line 2	1.47


New line, Same Plant = Fixed cost leverage achieved

- With new line commissioning, the installed capacity will scale up to 12 Cr.
- Expected to generate incremental revenue of 110-120 Cr per year with EBITDA margin expanding by 3-4%.




SVP: High Margin Products - to move up the value chain

SVP Expansion in Capacity (Qty Cr.)



- A 100% exports centric segment, Commissioned in 2005 and capacity tripled in 2008.
- Contributed 20% of the revenue in FY25. The segment operates at EBITDA margins of 22 – 27%.
- Incremental capacity is targeted at growing Inhalation Solution portfolio (Respules), OTC portfolio and Preservative Free unit doses.
- Started with low-NRV diluents and scaled revenue by moving up the value chain into formulations such as eye drops, nasal sprays, and respules.

Increasing share towards high margin product – Accounting to 20% (INR 55Cr) of the revenue in FY25






Location:

Block No: 872B, 873A, 874, 876
and 877 village Hariyala, District
Kheda Gujarat, India



Certifications & Compliance:

- ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018, WHO-GMP certified.
- Certified by the Food & Drugs Control Administration Gujarat.
- Conformity with WHO guidelines and GMP for formulations from Cambodia, Sudan, Philippines, and Zimbabwe.




Production Capabilities:

- Injections
- Oral Liquids
- Eye Care Products
- Respiratory Solutions
- Wound Cleaning Solutions



Utilization % across each Parenteral




FY25	Installed capacity (Units in crs)
LVP (excluding SteriPort)	5.7
SVP	20.9
SteriPort	6.6

Current Utilization of 96% - indicating strong demand visibility and efficient asset utilization.

Stable installed capacity combined with rising actual production highlights the company's operational discipline




Capex to drive future growth



Capex & Robust product pipeline to drive future growth

- Capacity Scale-up across all the lines
- Transition to Renewable Energy / Solar Power Integration
- Accelerated Product Pipeline / New Product Rollouts

Increased Focus on exports – Driving higher margins





Sales focus	Domestic branded generics sold under proprietary brand names.
Distribution network	Approximately 320 distributors and stockist across India.
Sales and marketing team strength	Approximately 96 personnel
Geographic Expansion	Primarily into regulated markets.

Export markets	21 countries as of Fiscal 2025.
Product range	<ul style="list-style-type: none"> LVP Pack Solutions: IV solutions, anti-fungal, and anti-protozoal formulations. SVP Pack Solutions: SWFI (Sterile Water for Injection), ophthalmic, injections, and respiratory products.
Market focus	<ul style="list-style-type: none"> Current Markets: Emerging and semi-regulated international markets. Expansion Targets: Regulated markets including the UK, Zimbabwe, Sudan, Cambodia, Philippines, and Ethiopia.
Product registrations	Portfolio of 47 products registered across 120 international jurisdictions.
New product Offerings	Inhalation Solutions (Respules) / Ophthalmics.



De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 40% since FY23

- Aggressively reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs).
- The equity denominator was significantly bolstered by a private placement of 2,000,000 shares at INR 100 each (including a INR 90 premium), which infused INR 20 Cr. in cash during FY25.
- Turnaround in profitability, shifting from a INR 2.1 Cr loss to a INR 10.5 Cr restated profit, naturally expanded the net worth base through increased retained earnings.





Setting up a Captive Solar power plant of 10.8 MW.



10.8 MW captive solar plant under implementation to structurally lower power costs



Commissioning targeted in Q1 FY27, benefits to be reflected in FY27 and onwards.



Total project cost: INR 34.8 Cr, largely debt-funded to preserve cash



Low equity outlay of INR 5.8 Cr, balance via term loan



Expected annual power cost savings of INR 9 Cr, improving EBITDA margins



Simple payback of 3.6 years (pre-interest) - fast capital recovery



Strengthens ESG profile with lower carbon footprint and cleaner energy mix



The Indian domestic formulation market is divided into chronic (53%) and acute (47%) segments in FY24.



Anti-diabetic (~9%) and cardiovascular (~13%) therapies lead the chronic segment, driven by rising chronic disease prevalence.



Chronic segment is expected to grow faster (8.5-9.5% CAGR) than the acute segment (7.0-8.0% CAGR) from FY24 to FY29.



Key acute therapies include anti-infectives, gastrointestinal, pain and analgesics treatments.

Key Therapy Areas In Domestic Formulation Market

Therapy Name	Share in Total Market FY19	Share in Total Market FY24	Share in Total Market FY29P	CAGR (FY19 - FY24)	CAGR (FY24- FY29P)
Cardiovascular	12.40	13.20	14.10	9.70	10.00 - 11.00
Anti-Infectives	12.60	12.30	11.70	8.00	7.50 - 8.50
Gastrointestinal	11.20	11.70	11.60	9.30	8.50 - 9.50
Anti-Diabetic	9.60	9.10	9.70	7.20	10.00 - 11.00
Vitamins / Minerals / Nutrients	8.60	8.80	8.90	8.80	9.00 -10.00
Respiratory	7.40	8.10	8.20	10.30	9.00 -10.00
Pain / Analgesics	6.80	7.10	6.90	9.50	7.50 - 8.50
Derma	7.60	6.60	6.40	5.40	7.50 - 8.50
Neuro /CNS	6.00	6.10	6.10	8.80	8.00 - 9.00
Gynecological	5.10	5.00	5.00	7.80	8.50 - 9.50

01 IV fluids industry in India to grow at a CAGR of 9-11% between fiscal 2024-2029.

02 The IV fluid market consists of normal saline, dextrose, lactate ringer, and electrolytes, has seen traction in recent years owing to growth of overall healthcare system in India.

03 The Indian IV fluids market is valued at ~Rs 45-47 billion in FY24, compared to ~Rs 29 billion in FY19.

Overview Of IV Fluids



Formulation exports grew by ~4.5% in FY23 after flat growth in FY22 due to pricing pressure in the US market.

India exported USD 12.3 bn worth of formulations to regulated markets in FY24, with 66% going to the US and 24% to Europe.


Exports to semi-regulated markets, mainly Africa, Asia, Russia, and Latin America, totaled USD 101bn in FY24, with Africa having the largest share.

New product launches, complex generics, and specialty drugs are expected to drive export growth, with pricing pressure expected to ease in the medium term.

Formulation exports to regulated markets are projected to grow by 11-13% in FY25, driven by new product launches in the US, Canada, and Japan. Long-term growth will be supported by the increasing focus on complex generics, specialty drugs, and biosimilars.



Formulation Export Trend For India





Mr. Bhavesh Patel
Chairman and Managing Director
30+ Years Of Experience

Bhavesh Patel is the Chairman and Managing Director and a promoter of the Company, associated since its incorporation. With over 30 years of industry experience, he is a Mechanical Engineer and a graduate in Finance.



Mr. Pratik Gandhi
Non-Executive Director
10+ Years Of Experience

Pratik Gandhi is the Non-Executive Director of our Company. With over 10 years of teaching experience, he is a qualified cost and work accountant.



Mr. Nimesh Patel
Non-Executive Director
3+ Years Of Experience

Nimesh Patel is the Non-Executive and Non-Independent Director of our company. He is a graduate of the Wharton School with a degree of Science in Economics.



Ms. Anjali Choksi
Independent Director 15+
Years Of Experience



Mr. Kshitij Patel
Independent Director 25+
Years Of Experience



Mr. Nitin Jain
Independent Director
20+ Years Of Experience

Anjali Choksi is an Independent Director of the Company. She is a qualified chartered accountant & holds Ph.D in philosophy. Over 15 years of experience as a partner at DNV & Co. – CA firm.

Kshitij Patel is the Independent and Non-Executive Director of the Company. A qualified chartered accountant & a partner of the firm Manubhai & Shah LLP.

Nitin Jain is an Independent Director of our Company. Having over 20 yrs experience as an Investment Banker & a partner of the firm Fulcrum Advisors. He is a graduate in Chemical Engineering & Postgraduate in management from IIM – Bengaluru.



Paras Mehta - Chief Financial Officer : A qualified Chartered Accountant with over 20 years of experience working with Indian and multinational companies.

Anil Rathi - Chief Operating Officer : A Graduate in Chemical Engineer & an MBA. He has over 25 years of experience in the pharmaceutical industries.

Vijay Kumar Walia - Chief Marketing Officer. He has over 20 years of experience in pharmaceutical industries.

Vimalkant Shrimali - Assistant Vice President (HRA & IT) : MBA graduate with varied experience in Indian as well as multinational companies having 20 years of experience

Dr. Chetan Sheth - Vice President (Quality & Regulatory Affairs) : A Pharmacist with a professional doctorate in management. He has over 15 years of experience in quality assurance and control.

Urmil Oza - Vice President (Utility & Engineering) : With over 30 years of experience, he holds a Instrumentation Engineering Degree and an MBA degree specializing in Marketing




Financial Performance – Q3 & 9M FY26


(Figures in INR Cr.)

Quarter Performance


Revenue



EBITDA and Margins (%)




PAT and Margins (%)




9M Performance


Revenue



EBITDA and Margins (%)



PAT and Margins (%)





Profitability increased by 51% in 9MFY26 on YoY basis



Sustained revenue trajectory:

Q3FY26 revenue stood at INR 75 cr, registering a 9.8% YoY growth, while 9MFY26 revenue reached INR 211 cr, marking a 3.97% YoY increase, reflecting steady demand and volume-led growth.



Operational discipline sustains EBITDA margins:

Operating EBITDA for Q3FY26 came in at INR 15 cr with margins at 20.62%, while 9MFY26 EBITDA increased 6.06% YoY to INR 45 cr, with margins improving by 42 bps YoY to 21.31%, highlighting effective cost control and operational efficiency.



Profitability strengthens on robust execution:

Net Profit for Q3FY26 rose to INR 5 cr, up 8.1% YoY, while 9MFY26 PAT grew 51.3% YoY to INR 9 cr, underscoring strong profitability momentum.



Improving earnings quality reflected in margins:

Q3FY26 PAT margin stood at 6.21%, while 9MFY26 PAT margin expanded by 139 bps YoY to 4.43%, driven by operating leverage and margin normalization.



Revenue Breakdown – Annual performance

(Figures in Rs. crs)

Revenue from operations	FY25	FY24	FY23
Revenue from contract with customers :			
Sale of products	267	272	253
Sale of services	5	6	5
Sub- total	272	278	258
Other operating revenue :			
Scrap sales	1	1	1
Export incentives	1	0	1
Total	275	280	259

Particulars	FY25	FY24	FY23
Revenues	275	280	259
Other Income	1	1	4
Total Income	276	282	263
Cost of materials consumed	101	86	101
Purchases of stock-in-trade	12	2	1
Changes in inventories of finished goods, work-in-process and stock-in-trade	(20)	17	53
Employee costs	36	33	32
Other expenses	85	85	73
Total Expenditure	215	223	206
EBITDA	61	59	56
Finance Costs	28	34	35
Depreciation and Amortization Expenses	18	20	18
Exceptional Items	-	-	-
PBT	15	5	3
Tax	4	2	5
PAT	11	4	(2)
Restated Other Comprehensive Income/(loss) for the period, net of tax	0	0	0
Restated Total Comprehensive Income/(loss) for the period	10	3	(2)



Balance Sheet

Assets	FY25	FY24	FY23
Non-Current Assets			
Property, plant and equipment	208	223	229
Capital work-in-progress	7	-	-
Right-of-use assets	9	5	9
Intangible assets	1	-	-
Non-Current Financial Assets	9	5	5
Non current tax assets(Net)	0	-	-
Other Non-Current Assets	11	1	0
Total Non-Current Assets	244	234	243
Current Assets			
Inventories	73	60	69
Trade receivables	50	48	54
Cash & Cash Equivalents	0	2	0
Bank Balance Other Than Cash	3	3	4
Other Financial Assets	-	-	-
Loans	1	0	0
Other Current Assets	11	6	5
Total Current Assets	138	118	131
Total Assets	382	352	374

Equities & Liabilities	FY25	FY24	FY23
Equity share capital	29	27	27
Other Equity	68	40	36
Net Worth	96	66	63
Non-Current Liabilities			
Non-Current Borrowings	132	149	176
Lease Liabilities	8	5	7
Deferred Tax Liabilities (Net)	30	30	32
Total Non-Current Liabilities	170	184	214
Current Liabilities			
Current Borrowings	63	56	40
Lease Liabilities	1	-	3
Current Tax Liabilities(Net)	1	1	3
Trade Payables	31	25	36
Provisions	8	7	6
Other Current Liabilities	2	2	1
Other Financial Liabilities	4	3	3
Contract Liabilities	6	8	6
Total Current Liabilities	115	102	97
Total Equity & Liabilities	382	352	374

Annexure

Our Product Categories -





Types of IV Fluids :

- Dextrose
- Normal Saline
- Combination Of Dextrose Normal Saline
- Ringer Lactate
- Electrolytes

Packaging Of Product :

- Single Port container
- Two Port container

Fill Volume Options :

- 100ml
- 250ml
- 500ml
- 1000ml

Innovative Technology :

- SteriPort bottles for IV fluid are manufactured with ISBM Technology using polypropylene as raw material



Therapeutic Segments	Products
Anti - fungal	Fluconazole
Anti – Pyretic	Paracetamol
Diuretics	Mannitol IV
Anti - Biotic	Linezolid
Quinolones	Ciprofloxacin, Levofloxacin, Gemifloxacin and Moxifloxacin
Anti - Anaerobic	Metronidazole Tinidazole

Product Focus :

- Injectables
- Ophthalmic
- Respiratory

Fill Volume Range :

- 2ml to 100ml

Technology :

- Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology

Notable Formulations:

- Ciprofloxacin
- Metronidazole
- Ofloxacin
- Paracetamol
- Fluconazole

Packaging Options:

- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)






Key Products :

- Lidocaine
- Potassium Chloride
- Magnesium Sulphate
- Calcium Chloride
- Calcium Gluconate



Injectables Portfolio



Pack Sizes :

- Offered in 5 ml & 10 ml

Products :

- Sterile Water for Injection (WFI)
- Normal Saline WFI



Diluents Overview





Therapeutic segments	Product
Ophthalmic (FFS)	Ciprofloxacin Ophthalmic Solution U.S.P. (0.3 % w/v)
Ophthalmic (FFS)	Timolol Maleate Eye Drops B.P. (0.5 % w/v & 0.25 % w/v)
Ophthalmic (FFS)	Gentamicin Eye Drops B.P. (0.3% w/v)
Ophthalmic (FFS)	Gentamicin Sulphate (0.3 % base) & Dexamethasone (0.1% w/v) Eye/Ear Drops
Ophthalmic (FFS)	Tobramycin (0.3% w/v) + Dexamethasone (0.1% w/v) Eye Drops
Ophthalmic (3 Piece)	Carboxymethyl Cellulose Sodium Eye Drops (0.5 % w/v)
Ophthalmic (3 Piece)	Hypromellose Eye Drops (0.5% w/v)
Ophthalmic (3 Piece)	Sodium Hyaluronate 0.3% w/v Eye Drops



Dosage Form :

- 5ml & 10ml



Applications :

- Including treatment for Infections, Glaucoma, Inflammation



Package Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack





Dosage Form :

- Available in 2.5ml



Applications :

- Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis.

Key Product :

- Budesonide Respiratory Suspension
- Salbutamol Respiratory Solution
- Salbutamol & Ipratropium Bromide Respiratory Solution
- Levosalbutamol Inhalation solution
- Levosalbutamol and Ipratropium Respiratory Solution





Product Types :

- OTC Eye Lubricants
- Wound Cleaning Solutions



Dosage Forms :

- Available in 5ml, 10 ml & 20 ml



Product :

- Sodium Chloride Eye Wash
- Wound Cleaning



LVP:	Large Volume Parenteral
SVP:	Small Volume Parenteral
ABFS:	Aseptic Blow Fill Seal
ISBM:	Injection Stretch-Blow Moulding
WFI:	Water For Injection
SWFI:	Sterile Water For Injection
WHO-GMP:	WHO Good Manufacturing Practices
PICs:	Pharmaceutical Inspection Co-operation Scheme
ISO:	International Organization for Standardization
SAL:	Sterility Assurance Level
OTC:	Over-the-Counter
ESG:	Environmental, Social, and Governance



Amanta Healthcare Ltd.
8th Floor, Shaligram Corporates,
C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India.
Telephone: 079 6777 7600
Email Id: cs@amanta.co.in
Website: www.amanta.co.in

Investor Relations
Go India Advisors

Name: Ms. Soumya Chhajer
Tel: +91-8619707750
Email: soumya@goindiaadvisors.com

Name: Ms. Shrutee Barve
Tel: +91-9892517329
Email: shrutee@goindiaadvisors.com